SPECIAL CARDIAC SAFETY CONCERNS

Shari L. Targum, MD, MPH, FACC
Chief, General Medicine Branch 1
Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT)
Office of Tissues and Advanced Therapies (OTAT)
CBER/FDA

FDA Clinical Investigator Training Course
November 15, 2018
Importance of Cardiac Safety Evaluation

• Several non-cardiac drugs withdrawn from market due to cardiac safety issues
• Characterize safety earlier in development?
• Do not want to delay development of promising therapies....
Detecting the problem

• Observation of events often precedes understanding
  -- mechanism of action (the “why” and “how”)
• Helpful to characterize mechanism (risk mitigation)
• You are the front line.
Detecting a safety signal

– *Common events:*  
  • Detect in clinical trials

– *Rare events:* sometimes detect in clinical trials (e.g., Stevens-Johnson) or via  
  • Risk biomarkers  
  • Epidemiologic studies (e.g., case-control)
Detecting a safety signal (cont.)

– *Spontaneous events* ↑ *rate with drug*: single event usually *not* interpretable; detect via:
  • adequately powered controlled trial
  • compare to background rate
  • epidemiologic study (large hazard ratio)

– Include vulnerable populations
DRUG-INDUCED QT PROLONGATION AND PROARRHYTHMIA
QT Interval

• Highly variable (time of day, autonomic tone)
• Can be prolonged because of:
  – Heart disease
  – Electrolyte abnormalities
  – Drugs
Torsade de Pointes (TdP)

- Rare, life-threatening; might not be detected in a development program
QT interval: safety biomarker

- “Thorough QT” study
- Threshold for potential importance set low (10 msec prolongation)
- “Negative study”—routine phase 3 monitoring
- Failure to rule out 10 msec—heightened phase 3 monitoring
Era of Thorough QT studies

Pro:
• No further drug withdrawals due to TdP risk

Con:
• Expensive
• Relationship to risk crude and not constant
• Interest in alternative approaches to assess risk of proarrhythmia
DRUG-INDUCED VALVULAR DISEASE
Weight Loss and Appetite Suppressants

• Fenfluramine (1973): approved for short-term use
  – Increased serotonin, associated with depression

• Dexfenfluramine (1996) thought to be “safer”

• Fen-Phen: never approved, used off-label for long-term management
24 women, no prior heart disease, mean treatment duration 11 months.

The New England Journal of Medicine

VALVULAR HEART DISEASE ASSOCIATED WITH FENFLURAMINE–PHENTERMINE

HEIDI M. CONNOLLY, M.D., JACK L. CRARY, M.D., MICHAEL D. McGOON, M.D., DONALD D. HENSRUD, M.D., M.P.H., BROOKS S. EDWARDS, M.D., WILLIAM D. EDWARDS, M.D., AND HARTZELL V. SCHAFF, M.D.
5-HT 2B Receptor Pathway

Source: Bhattacharyya 2009
RISK OF MYOCARDIAL INFARCTION
Rofecoxib (Vioxx)

• Originally approved (1999) for acute pain (up to 5 days), dysmenorrhea, and osteoarthritis (12.5 mg and 25 mg/day).
• COX-2 inhibition premise: analgesia with less GI toxicity
• Dose-related hypertension and edema
• No cardiovascular signal observed at approval.
• Controlled studies were short-term
VIGOR Study

• Large, randomized double-blind trial
• Vioxx 50 mg/day or Naproxen 500 mg twice/day
  – no placebo arm
• Primary endpoint was GI events
• Rheumatoid arthritis, mostly < 65 years
  – Population at ↑ risk of cardiovascular events
Confirmed Thrombotic Cardiovascular Serious Adverse Experiences in Rheumatoid Arthritis Patients in the VIGOR Study
Time-to-Event Plot (All Patients Randomized)
Updated Application Data
APPROVe Study

• Three-year, placebo-controlled study
• Primary endpoint: prevention of colorectal polyps
• Terminated early—↑ incidence of cardiovascular events in subjects treated with Vioxx
• Vioxx withdrawn (2004)
Diabetes drugs and cardiac risk

• Guidance evaluating CV risk in new therapies to treat type 2 diabetes (2008)
  – Design 2/3 trials to allow meta-analysis
  – Blinded endpoint adjudication committee
  – Include higher risk subjects
  – Prespecified upper bound
Groups interested in cardiac safety

• Cardio-Oncology (American College of Cardiology, American Society of Clinical Oncology)
• Cardiac Safety Research Consortium
Final Thoughts

• Much has been learned; much work remains
• How best to screen? Monitor? Reduce risk?
• Can testing be done earlier and/or at less cost?
Contact Information

- Shari L Targum, MD, MPH
  shari.targum@fda.hhs.gov

- Regulatory Questions:
  OTAT Main Line – 240 402 8190
  Email: OTATRPMS@fda.hhs.gov and Lori.Tull@fda.hhs.gov

- OTAT Learn Webinar Series:
  http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/ucm232821.htm

- CBER website: www.fda.gov/BiologicsBloodVaccines/default.htm

- Phone: 1-800-835-4709 or 240-402-8010

- Consumer Affairs Branch: ocod@fda.hhs.gov

- Manufacturers Assistance and Technical Training Branch: industry.biologics@fda.hhs.gov

- Follow us on Twitter: https://www.twitter.com/fdacber